Diabetes

Top Story

EXSCEL: Exenatide meets primary safety objective for CV risk in type 2 diabetes

May 23, 2017

Top-line results from the EXSEL trial show the GLP-1 receptor agonist exenatide extended release met the primary safety objective of non-inferiority for major adverse cardiac events in patients with type 2 diabetes when compared with placebo, Astra Zeneca announced in a press release.

The Exenatide Study of Cardiovascular Event Lowering trial compared the effect of once-weekly exenatide extended release (Bydureon) added to usual care with placebo on the risk for the composite endpoint of CV death, non-fatal myocardial infarction or non-fatal stroke, in adults with type-2 diabetes at a wide range of CV risk. The EXSCEL trial is the largest and most inclusive patient population of any CV outcomes trial of the GLP-1 receptor agonist class conducted to date, including more than 14,000 patients from 35 countries, according to the release.

Meeting News

New therapies offer options for patients with diabetes, heart failure

May 6, 2017
AUSTIN, Texas — New anti-diabetic therapies offer options for patients with type 2 diabetes and heart failure, whereas several ongoing and longer-term studies are…
Meeting News

Resveratrol may reduce arterial stiffness in patients with diabetes

May 5, 2017
Resveratrol reversed arterial stiffness in patients with type 2 diabetes, according to an abstract presented at the American Heart Association’s Arteriosclerosis…

Trial to study subcutaneous ICD in patients with diabetes, MI commences

April 29, 2017
An international trial to study the survival benefit of a subcutaneous implantable cardioverter defibrillator system has begun enrolling patients, according to a press…
In the Journals Plus

Diabetes increases all-cause mortality risk in chronic heart failure

March 8, 2017
Adults with chronic heart failure and diabetes have higher risks for all-cause death, cardiovascular death and hospitalization for worsening heart…

In the Journals Plus

Probiotic supplementation may reduce hypertension, dyslipidemia in type 2 diabetes

March 8, 2017
Adults with type 2 diabetes randomly assigned to probiotic supplementation saw a small reduction in blood pressure, total cholesterol, LDL…

Expert discusses relationship between autoimmune disease, diabetes, CVD

February 28, 2017
Many of the risk factors for heart disease, including high BP, high LDL, smoking and obesity, are well-known, but some, such as autoimmune disease…

In the Journals Plus

Obesity influences relationship between CMV infection, metabolic syndrome in women

February 28, 2017
Women with extreme obesity who are seropositive for human cytomegalovirus are less likely to develop metabolic syndrome vs. women of normal weight…

In the Journals

Reminder devices not superior to usual care for medication adherence

February 28, 2017
Among nonadherent patients who were taking up to three medications for common chronic conditions, low-cost reminder devices did not improve adherence…

In the Journals Plus

NHANES: HbA1c associated with mortality risk in older adults

February 27, 2017
In older adults, an HbA1c greater than 8% was associated with increased risks for all-cause, cardiovascular and cancer-related deaths, according to…

In the Journals

Reminders tied to life, calendar events fail to increase medication adherence

February 27, 2017
Researchers tested medication reminders linked to “fresh-start” dates, defined as life and calendar events indicating the start of new…

In the Journals Plus

STAMPEDE: Sustained glycemic benefit observed 5 years after gastric bypass in type 2 diabetes, obesity

February 21, 2017
Patients with type 2 diabetes and mild to moderate obesity who underwent Roux-en-Y gastric bypass or sleeve gastrectomy saw sustained improvements in…

In the Journals

Benefits of statin therapy outweigh diabetes risk

February 20, 2017
In a commentary published in The American Journal of Medicine, experts wrote that the CV benefits of statins outweigh any diabetes-related risk they…

In the Journals

DAPT, aspirin monotherapy confer similar outcomes in patients with diabetes after CABG

February 17, 2017
New data suggest that use of dual antiplatelet therapy may not be clinically warranted in patients with diabetes post-CABG. According to data…

More Headlines »
Advertisement
Advertisement